27.89 % to Target, Canaccord Genuity Maintains ‘”Buy”’ Rating on Zymeworks Inc (ZYME) Shares Today

May 17, 2018 - By Winifred Garcia

Zymeworks Inc (ZYME) Rating Reaffirmed

They currently have a $21.0000 TP on Zymeworks Inc (ZYME). The target price by Canaccord Genuity would suggest a potential upside of 27.89 % from the company’s previous stock close. This has been revealed to investors in a research report on 16 May.

Zymeworks Inc. (NYSE:ZYME) Ratings Coverage

Among 4 analysts covering Zymeworks Inc. Common Shares (ZYME), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Zymeworks Inc. Common Shares has $25 highest and $1800 lowest target. $17’s average target is 3.53% above currents $16.42 stock price. Zymeworks Inc. Common Shares had 4 analyst reports since March 19, 2018 according to SRatingsIntel. The firm has “Equal-Weight” rating by Barclays Capital given on Friday, May 11. The firm earned “Buy” rating on Wednesday, May 2 by Canaccord Genuity.

The stock decreased 0.91% or $0.15 during the last trading session, reaching $16.42. About 135,093 shares traded or 295.03% up from the average. Zymeworks Inc. (ZYME) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await Zymeworks Inc. (NYSE:ZYME) to report earnings on August, 14. They expect $-0.69 EPS, down 9.52 % or $0.06 from last year’s $-0.63 per share. After $-0.83 actual EPS reported by Zymeworks Inc. for the previous quarter, Wall Street now forecasts -16.87 % EPS growth.

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company has market cap of $416.15 million. The company's lead product candidate include ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast, gastric, and ovarian cancers. It currently has negative earnings. It is also developing ZW33, a bispecific anti-human epidermal growth factor receptor 2 antibody-drug conjugate that is in preclinical development stage for the treatment of breast and ovarian cancers.

More notable recent Zymeworks Inc. (NYSE:ZYME) news were published by: Streetinsider.com which released: “Zymeworks (ZYME) Announces Expanded Bispecific Antibody Collaboration with Celgene Corp. (CELG)” on April 23, 2018, also Seekingalpha.com with their article: “Zymeworks expands IO collaboration with Daiichi Sankyo” published on May 15, 2018, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For May 14, 2018” on May 14, 2018. More interesting news about Zymeworks Inc. (NYSE:ZYME) were released by: Streetinsider.com and their article: “UPDATE: Barclays Upgrades Zymeworks (ZYME) to Equalweight” published on May 11, 2018 as well as Investingnews.com‘s news article titled: “Notes from the Floor: Bloom Burton & Co., Day 1” with publication date: May 02, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.